Funding for this research was provided by:
Received: 30 September 2021
Accepted: 2 September 2022
First Online: 8 September 2022
: The RESTART study is being conducted in compliance with the principles of the Declaration of Helsinki and Clinical Trials Act of Japan, and it was approved by the certified central review board of Clinical Research Network Fukuoka (CRB7180004) on 12 February 2021. This trial was registered in the Japan Registry for Clinical Trials as jRCTs071200102 on 25 February 2021. The latest version (version 1.2) of the study protocol was reviewed and approved by the certified central review board of Clinical Research Network Fukuoka on 17 June 2021. Written informed consent is obtained from all participants.
: Not applicable.
: YS, YT, SS, and IO have received personal fees and/or grants from Chugai Pharma.